Before its COVID-19 era hype, ivermectin was already a wonder drug for parasitic infections. Its renewed interest underscores the need for effective COVID-19 treatments and communication on proper research study design and analysis.
A young cancer researcher made a big splash when she discovered that inhibiting DNA damage response proteins sensitizes treatment-resistant lung cancer cells to immunotherapy.
Targeting oncogenic transcription factors like MYC is challenging, but researchers found a way to target its regulator, WDR5, for degradation, exemplifying the capacity of protein degraders to target the “undruggable.”
People metabolize drugs differently, changing the effectiveness and toxicity of drugs between individuals. Genetic testing to identify mutations in metabolic genes that may affect how someone processes a drug is an important step towards precision medicine that is becoming more common in the clinic.
Philip Yeske was an organic chemist for more than 20 years, but when his daughter died from the rare mitochondrial disorder Leigh Syndrome, he turned to connecting researchers, patients, and law makers to speed the discovery of treatments.
The long history of insulin discovery and its development for treating diabetes is marked with determination and serendipity, collaboration and controversy.
Pregnant people with mental health disorders such as depression or bipolar disorder often face an impossible decision: risk their health or their future child's health by discontinuing or continuing their medication.
Psilocybin research was "outlawed" in the 70s, but it's back now. It may offer a powerful new tool for treating addictions to substances such as alcohol, cigarettes, and opioids.
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.